AVX754 (a New Nucleoside Reverse Transcriptase Inhibitor [NRTI]) to Treat Drug-resistant HIV

• Status: Completed
• Trial end date: 2008-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The study will measure how safe and effective AVX754 (a new drug for the treatment of HIV) is in treating HIV-1 infected people who have failed treatment with lamivudine.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Avexa
• Treatments: Lamivudine; Reverse Transcriptase Inhibitors

Criteria

Inclusion Criteria:

• HIV-1 infected

• M184V mutation in reverse transcriptase

• Currently taking lamivudine

• Viral load >2000 copies/ml

Exclusion Criteria:

• Hepatitis B surface antigen positive

• Pregnant or breastfeeding females

• Hepatitis C RNA positive and requiring treatment